Nebenwirkungen · Cyramza
Cyramza 10 mg/ml concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 15
HOS-130151 · Präparat HOS-096857
System Organ Class Common Uncommon Rare Not known (MedDRA) Neoplasms benign, Haemangioma malignant and unspecified (including cysts and polyps) Blood and lymphatic Thrombotic system disorders microangiopathy Endocrine disorders Hypothyroidism Nervous system Posterior disorders reversible encephalopathy syndrome Cardiac disorders Cardiac failurea Vascular disorders Aneurysms and artery dissections Respiratory, thoracic Dysphonia and mediastinal disorders a In the post-marketing setting, cardiac failure has been observed for ramucirumab mostly in combination with paclitaxel. See section 4.4.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-16T14:55:00Z · SHA-256 24154ea821ed10186fb564202f2c172a36dd6da94cb438714c99337075c53ca0 · Passage b9cc16766ee2ede9374ec5e6ecc375fd34b1dd29859e25c4469c20ca9b67ad77 · Zeichen 8476–9830 im Abschnitt